New opioid law protects users from prosecution while targeting traffickers
S. 5383 — End Gas Station Heroin Act · Filed by Bernie Moreno (R-OH) · Introduced Aug 8, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill schedules two kratom alkaloids (7-hydroxymitragynine and mitragynine pseudoindoxyl) as Schedule I controlled substances when concentrated or synthesized, but exempts natural kratom products below specified thresholds. It also creates a new enforcement mechanism targeting emerging synthetic opioids sold in commercial distribution ("gas station heroin"), treating them as Schedule I drugs for enforcement purposes while explicitly protecting users from prosecution for simple possession or personal use.
Why we flagged it
The bill's core mechanism is scheduling emerging synthetic opioids for enforcement while protecting users from prosecution, combined with a kratom alkaloid scheduling that exempts natural products. This is a public-health and law-enforcement measure, not a deregulation or corporate carve-out.
What the text implies
- The kratom exemption (natural products below 1 mg/g threshold) effectively legalizes the existing kratom market while banning concentrated/synthetic extracts, creating a regulatory boundary that may shift consumer demand toward whole-plant products.
- The 'covered emerging synthetic opioid' definition relies on Attorney General regulations to identify substances by potency and receptor activity, delegating significant scheduling authority to the executive branch without requiring formal CSA scheduling procedures.
The full analysis lists 4 implications of this text.
Who stands to gain
legal kratom producers and retailers (protected by natural-product exemption); pharmaceutical companies with approved opioid medications (explicitly excluded from enforcement)